Navigation Links
Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
Date:6/1/2011

er-stage clinical studies."

SB1518 is a small molecule JAK2-selective kinase inhibitor, which has demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in myeloproliferative disorders such as MF. It is estimated that approximately 50% of patients with MF possess the JAK2 mutation.

2011 ASCO Annual MeetingPoster Board 7, Abstract No. 6515 (2-6 p.m. CDT, Friday, June 3)Poster Discussion Session (5-6 p.m. CDT, Friday, June 3)Phase 2 Study of SB1518, an Orally Available Novel JAK2 Inhibitor, in Patients with Myelofibrosis

SB1518 showed promising efficacy in symptomatic MF patients with splenomegaly. Once daily dosing was well tolerated, with manageable grade 1 and 2 GI toxicity as the main side effect. Patients with significantly impaired hematopoiesis could receive full-dose daily of SB1518 without exacerbating hematocytopenias. Thirty-three patients with MF were enrolled. Median spleen enlargement by physical examination (PE) was 18 cm below the LCM. Of 30 patients assessed by MRI, 29 had a spleen volume reduction; 17 (57%) had a reduction of > 25%. Of 31 patients assessed by PE, 12 (39%) had a reduction of >50%, and seven (23%) had a reduction of 100%. Results showed that a 50% reduction in spleen length by PE corresponded to a 25% reduction in spleen volume by MRI (p=0.043). Intensity of MF-related symptoms decreased by 40-65% in patients treated for 6 months. The most common treatment-related toxicities were diarrhea (81%; 6% Gr 3), nausea (41%; all Gr 1/2), vomiting (22%; all Gr 1/2), and fatigue (9%; all Gr 1/2). These events were readily managed. At six months, 21 patients remain on therapy. Significant neutropenia and thrombocytopenia were not seen (no Gr 3/4 events). SB1518 was tolerated equally well by patients with normal platelet counts and t
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
2. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
3. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
4. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
5. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
6. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
10. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
11. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 GSI Group Inc. (NASDAQ: ... leader and supplier of precision photonics and motion control ... industrial technology markets, today reported financial results for the ... all financial results in this press release are GAAP ... the fourth quarter of 2014, GSI generated revenue of ...
(Date:3/4/2015)... PARK, Calif. , March 4, 2015  Nevro ... company that has developed and commercialized an innovative, evidence-based ... announced that it will release financial results for the ... close on Wednesday, March 18, 2015. Company management will ... Time (4:30 p.m. Eastern Time) on Wednesday, March 18, ...
(Date:3/4/2015)... , March 4, 2015 The March 3, 2015, order ... drugs must change their products, labels to clarify the drugs, ... attack and stroke is necessary to protect the public from ... a partner at Simmons Hanly Conroy . ... labels that the products – currently taken by millions of ...
Breaking Medicine Technology:GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 16GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 17GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 18GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 19GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 20GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 21GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 23GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 24GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 25GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 26GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 27GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 28GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 29GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 30GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 31GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 32GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 33Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2
... Corporation (NASDAQ: HSKA ; "Heska"), a leading ... to veterinarians, announced today the intent to collaborate with ... disorders.  The parties are to explore unique technologies in ... use in the veterinary market.      "Heska ...
... 14, 2011 Berger Health System, recognized as one ... Association, upgrades to AutoCarousel® HD by Talyst, a leader ... control, and has a built-to-last 10 years guarantee. ... five years, is also implementing AutoPharm®, AutoPack™ and AutoLabel® ...
Cached Medicine Technology:Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 2Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 3Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2
(Date:3/4/2015)... March 04, 2015 Ultraman Florida is ... mile swim, 261.4 mile bike, and 52.4 mile run. ... time of 24:45:45. , "This race was awesome and ... wonderful team and sponsors for supporting me through every ... 2015 had a total of 40 select participants invited ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief Medical ... the FDA’s recent decision to issue a warning ... FDA’s conclusions are not supported by science, and that ... deficiency. , “The FDA appears to have developed a ... Dr. Asandra. “There is not nearly enough evidence to ...
(Date:3/4/2015)... 2015 TROY Healthcare Solutions will be ... the ultimate level of security for prescriptions, in Houston, ... Plaza Medical Center located at 6633 Travis Street from ... 7 AM, TROY Healthcare Solutions will host a continental ... offer brief presentations each hour to introduce attendees to ...
(Date:3/4/2015)... March 04, 2015 Cook For Your ... that teaches healthy cooking to people touched by cancer, ... Lodge. The program, run by founder Ann Ogden, will ... Sport Management. The unique partnership will expand the program ... founded CFYL in 2007. After going through her own ...
(Date:3/4/2015)... 2015 Smokers across America are the ... 'We Love Smokers' from Aqua-Tine, the new brand that ... "It’s important to establish a clear point of view ... idea, 'We Love Smokers' elevates the Aqua-Tine brand, gives ... created a bold tone of voice that is also ...
Breaking Medicine News(10 mins):Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... March 24 Epiphany Biosciences announced today that ... the Food and Drug Administration (FDA) to study ... valomaciclovir (EPB-348) as an adjunctive therapy in the ... possess potent antiviral activity in vitro against a ...
... Reverse Split Ratio of Outstanding Cellegy Common Stock Expected ... Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced ... Corporation approved the previously announced merger of the two ... The transaction, which is subject to customary closing ...
... to be affected into 2010, according to Millennium ... Millennium Research Group,s (MRG,s) US Markets for Small-Joint ... elbow, digit, ankle, and wrist) and arthrodesis devices ... seen in recent years will continue despite the ...
... According to a new Harris Interactive/HealthDay poll, the ... afford medical care and prescription medications.(1) In addition, a ... Americans went without needed prescription medications in 2007 due to ... Experts predict these statistics are likely to get worse in ...
... , ... Dallas (Vocus) March 24, 2009 -- Broadlane announced ... with Broadlane. Wuesthoff will continue to access Broadlane,s unparalleled national ... help manage its approximate $53 million in annual spend for its ...
... March 24 Regal International, Inc., doing business ... been appointed by EMK Products, LLC to be ... Care Product line. Under the agreement, Beauty Beverly ... the development and management of internet affiliates, marketing ...
Cached Medicine News:Health News:Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS) 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 3Health News:Job Loss Means Fewer Americans Have Health Care Coverage: How Will the Economic Downturn Affect the Small-Joint Implant Market? 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 3Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 4Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 2Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 3Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 4Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 2Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 3
... System provides easy-to-use features, auto iris, white ... camera head construction is based on Solos ... 1-Chip Camera System, Domestic (GS 9900-NTSC) includes: ... with power cord and video cables , ...
... The 3-Chip Camera System offers 800+ ... generator, auto iris, automatic gain control, and ... , ,Complete 3-Chip Camera System for ... , (MS 1000-01) Camera Control Unit (CCU) ...
Provides a combination of concentrated cold / hot and compression for the elbow...
Provides a combination of concentrated cold / hot and compression for the neck...
Medicine Products: